
|Articles|October 15, 2003
Intravitreal triamcinolone may be beneficial option for DME
New Brunswick, NJ-Results of a retrospective study suggest that intravitreal triamcinolone acetonide may be a beneficial treatment for eyes with diabetic macular edema (DME), said Janet J. Chieh, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Improved grading scales for oncology drugs causing ocular adverse events
5













































.png)


